← Leaderboards
Mariusz A Wasik
University Of Pennsylvania
$8,531,349
Attributed
$11,159,286
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,159,286 · 5
By mechanism
R01$11,159,286 · 5
Top collaborators
- Jerry D Glickson6 shared
- Kavindra Nath5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Alain H Rook$9,745,732
- Stephan A Grupp$7,570,044
- Xiaolu Yang$22,144,051
- Meenhard Herlyn$50,214,821
- Stewart Lessin$400,186
Others in their field
Top investigators on “Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
LymphomaIn VitroCellsMalignant NeoplasmsIn VivoSignal TransductionGenesCell LineCancer CellProteinsSignal PathwayTumorTissuesPathway InteractionsBaseCell PhysiologySmall MoleculePhosphotransferasesCancer TypeGene ExpressionInhibitor/AntagonistKinase InhibitorTranscription FactorResponse
Grant awards (32)
Metabolic Imaging of Targeted Therapies in Cancer$609,855
R01 · FY2025 · CA
Metabolic Imaging of Targeted Therapies in Cancer$579,363
R01 · FY2024 · CA
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition$477,166
R01 · FY2024 · CA
Metabolic Imaging of Targeted Therapies in Cancer$597,658
R01 · FY2023 · CA
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition$492,237
R01 · FY2023 · CA
Metabolic Imaging of Targeted Therapies in Cancer$625,478
R01 · FY2022 · CA
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition$492,237
R01 · FY2022 · CA
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition$501,912
R01 · FY2021 · CA
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition$516,669
R01 · FY2020 · CA
Novel role of STAT3 in NPM/ALK-induced oncogenesis$272,958
R01 · FY2013 · CA · contact PI
Novel role of STAT3 in NPM/ALK-induced oncogenesis$290,381
R01 · FY2012 · CA · contact PI
Novel role of STAT3 in NPM/ALK-induced oncogenesis$290,381
R01 · FY2011 · CA · contact PI
Novel role of STAT3 in NPM/ALK-induced oncogenesis$299,362
R01 · FY2010 · CA · contact PI
Jak/STAT signaling in human T-cell lymphomas$249,891
R01 · FY2010 · CA · contact PI
Novel role of STAT3 in NPM/ALK-induced oncogenesis$299,362
R01 · FY2009 · CA · contact PI
Jak/STAT signaling in human T-cell lymphomas$249,891
R01 · FY2009 · CA · contact PI
Jak/STAT signaling in human T-cell lymphomas$249,891
R01 · FY2008 · CA · contact PI
(m) TOR signaling in EBV-associated lymphomas$263,002
R01 · FY2007 · DE · contact PI
Jak/STAT signaling in human T-cell lymphomas$249,891
R01 · FY2007 · CA · contact PI
Dysregulation of STAT3 in ALK-induced oncogenesis$294,073
R01 · FY2006 · CA · contact PI
(m) TOR signaling in EBV-associated lymphomas$270,857
R01 · FY2006 · DE · contact PI
Jak/STAT signaling in human T-cell lymphomas$256,606
R01 · FY2006 · CA · contact PI
Dysregulation of STAT3 in ALK-induced oncogenesis$301,150
R01 · FY2005 · CA
(m) TOR signaling in EBV-associated lymphomas$277,375
R01 · FY2005 · DE
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA$249,638
R01 · FY2005 · CA
Dysregulation of STAT3 in ALK-induced oncogenesis$301,150
R01 · FY2004 · CA
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA$249,638
R01 · FY2004 · CA
Dysregulation of STAT3 in ALK-induced oncogenesis$301,150
R01 · FY2003 · CA
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA$249,638
R01 · FY2003 · CA
Dysregulation of STAT3 in ALK-induced oncogenesis$301,150
R01 · FY2002 · CA
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA$249,638
R01 · FY2002 · CA
ABERRANT JAK/STAT SIGNALING IN CUTANEOUS T CELL LYMPHOMA$249,638
R01 · FY2001 · CA